217 related articles for article (PubMed ID: 31370904)
1. The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization.
Kallergi G; Tsintari V; Sfakianakis S; Bei E; Lagoudaki E; Koutsopoulos A; Zacharopoulou N; Alkahtani S; Alarifi S; Stournaras C; Zervakis M; Georgoulias V
Breast Cancer Res; 2019 Aug; 21(1):86. PubMed ID: 31370904
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.
Roumeliotou A; Strati A; Chamchougia F; Xagara A; Tserpeli V; Smilkou S; Lagopodi E; Christopoulou A; Kontopodis E; Drositis I; Androulakis N; Georgoulias V; Koinis F; Kotsakis A; Lianidou E; Kallergi G
Cells; 2024 May; 13(9):. PubMed ID: 38727318
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis.
Kallergi G; Hoffmann O; Bittner AK; Papadimitriou L; Katsarou SD; Zacharopoulou N; Zervakis M; Sfakianakis S; Stournaras C; Georgoulias V; Kimmig R; Kasimir-Bauer S
Ther Adv Med Oncol; 2020; 12():1758835919895754. PubMed ID: 32426042
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic Characterization of Circulating Tumor Cells Isolated from Non-Small and Small Cell Lung Cancer Patients.
Roumeliotou A; Pantazaka E; Xagara A; Dimitrakopoulos FI; Koutras A; Christopoulou A; Kourelis T; Aljarba NH; Alkahtani S; Koinis F; Kotsakis A; Kallergi G
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612166
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements.
Kallergi G; Aggouraki D; Zacharopoulou N; Stournaras C; Georgoulias V; Martin SS
Breast Cancer Res; 2018 Jul; 20(1):67. PubMed ID: 29976237
[TBL] [Abstract][Full Text] [Related]
6. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
11. The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value.
Bahnassy AA; Saber MM; Mahmoud MG; Abdellateif MS; Abd El-Mooti Samra M; Abd El-Fatah RM; Zekri AN; Salem SE
Mol Biol Rep; 2018 Dec; 45(6):2025-2035. PubMed ID: 30229477
[TBL] [Abstract][Full Text] [Related]
12. ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.
Appaiah H; Bhat-Nakshatri P; Mehta R; Thorat M; Badve S; Nakshatri H
Cancer Biol Ther; 2010 Sep; 10(6):600-14. PubMed ID: 20603605
[TBL] [Abstract][Full Text] [Related]
13. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.
Androulakis N; Agelaki S; Perraki M; Apostolaki S; Bozionelou V; Pallis A; Kalbakis K; Xyrafas A; Mavroudis D; Georgoulias V
Br J Cancer; 2012 Jun; 106(12):1917-25. PubMed ID: 22669159
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.
Cristofanilli M; Broglio KR; Guarneri V; Jackson S; Fritsche HA; Islam R; Dawood S; Reuben JM; Kau SW; Lara JM; Krishnamurthy S; Ueno NT; Hortobagyi GN; Valero V
Clin Breast Cancer; 2007 Feb; 7(6):471-9. PubMed ID: 17386124
[TBL] [Abstract][Full Text] [Related]
16. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of circulating tumor cells in metastatic breast cancer.
Lang JE; Scott JH; Wolf DM; Novak P; Punj V; Magbanua MJ; Zhu W; Mineyev N; Haqq CM; Crothers JR; Esserman LJ; Tripathy D; van 't Veer L; Park JW
Breast Cancer Res Treat; 2015 Jan; 149(1):121-31. PubMed ID: 25432738
[TBL] [Abstract][Full Text] [Related]
18. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.
Mego M; Cholujova D; Minarik G; Sedlackova T; Gronesova P; Karaba M; Benca J; Cingelova S; Cierna Z; Manasova D; Pindak D; Sufliarsky J; Cristofanilli M; Reuben JM; Mardiak J
BMC Cancer; 2016 Feb; 16():127. PubMed ID: 26896000
[TBL] [Abstract][Full Text] [Related]
19. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract][Full Text] [Related]
20. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
